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Abstract
High-grade serous ovarian cancer (HGSC) disseminates early and extensively throughout the peritoneal space,
causing multiple lesions that are a major clinical problem. The aim of this study was to investigate the cellular
composition of peritoneal tumour deposits in patient biopsies and their evolution in mouse models using
immunohistochemistry, intravital microscopy, confocal microscopy, and 3D modelling. Tumour deposits from the
omentum of HGSC patients contained a prominent leukocyte infiltrate of CD3+ T cells and CD68+ macrophages,
with occasional neutrophils. Alpha-smooth muscle actin+ (α-SMA+) pericytes and/or fibroblasts surrounded these
well-vascularized tumour deposits. Using the murine bowel mesentery as an accessible mouse peritoneal tissue
that could be easily imaged, and two different transplantable models, we found multiple microscopic tumour
deposits after i.p. injection of malignant cells. Attachment to the peritoneal surface was rapid (6–48 h) with an
extensive CD45+ leukocyte infiltrate visible by 48 h. This infiltrate persisted until end point and in the syngeneic
murine ID8 model, it primarily consisted of CD3+ T lymphocytes and CD68+ macrophages with α-SMA+ cells
also involved from the earliest stages. A majority of tumour deposits developed above existing mesenteric blood
vessels, but in avascular spaces new blood vessels tracked towards the tumour deposits by 2–3 weeks in the
IGROV-1 xenografts and 6 weeks in the ID8 syngeneic model; a vigorous convoluted blood supply was established
by end point. Inhibition of tumour cell cytokine production by stable expression of shRNA to CXCR4 in IGROV-1
cells did not influence the attachment of cells to the mesentery but delayed neovascularization and reduced
tumour deposit size. We conclude that the multiple peritoneal tumour deposits found in HGSC patients can be
modelled in the mouse. The techniques described here may be useful for assessing treatments that target the
disseminated stage of this disease.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
There may be controversy about the cell and tissue
origin of high-grade serous ovarian cancer (HGSC)
[1,2], but there is no doubt that by the time of diag-
nosis, this most common and lethal of the ‘ovarian’
malignancies has spread extensively throughout the
peritoneal space [3,4], presenting a fundamental clin-
ical problem. After optimal cytoreduction by surgery
and chemotherapy, many microscopic nodules remain,
and in these areas chemoresistant cells may develop.
The reason why high-grade serous cancers are only
detected once they have spread throughout the peri-
toneum is that small asymptomatic primary lesions,
whether they develop on the surface of the ovary or
the distal fimbria of the Fallopian tube, are able to
generate multiple micro-metastases by the dissemina-
tion of malignant cells into the peritoneum [2,5].
There is as yet no appropriate genetic model of
HGSC that accurately recapitulates the p53 mutation
and general genomic instability characteristic of this
malignancy [6], but intraperitoneal injection of malig-
nant cells in xenogeneic or syngeneic models gen-
erates large intraperitoneal tumours and ascites fluid
with tumour growth usually measured by biolumines-
cent imaging of luciferase-transfected cells or weight
of macroscopic resected tumours [7–10]. The devel-
opment of microscopic peritoneal metastases has not
been studied in detail and it is not known if this is
a valid model for the human situation. Our aim was
to study the natural history and cellular composition
of peritoneal metastases in mouse models and relate
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our findings to the human disease. We conclude that
this clinical problem can be reproduced in mouse mod-
els; describe techniques that could enhance our under-
standing of peritoneal tumour spread and be useful in
the development of novel treatments; and show how
shRNA to the chemokine receptor CXCR4 had a sig-
nificant effect on the development of intraperitoneal
tumour deposits.
Materials and methods
Cell lines
IGROV-1 (NCI) and the ID8 (MOSEC) malignant cells
(provided by K Roby, University of Kansas, Kansas
City, KS, USA) were used for this study. IGROV-
1 cells were cultured in RPMI with 10% FCS and
ID8 cells were cultured in DMEM with 4% FCS and
insulin transferrin sodium selenite supplement (Sigma
Aldrich, Dorset, U.K.). The human cell line most
recently underwent 16 loci STR authentication (LGC
Standards, London, UK) in September 2011. Both
cell lines were infected with a lentiviral eGFP con-
struct (pHRSIN-CSGW-dNotI) to express an eGFP
construct (kindly provided by Dr Y Ikeda, Mayo Clinic,
Rochester, MN, USA), as described previously by
Kulbe et al [8]. IGROV-1 cells were also transfected
with SUPER RNAi™ plasmids containing two different
shRNA sequences targeting CXCR4, or a control plas-
mid containing scrambled RNA (IGROV-Scrambled).
Cells were transfected using Lipofectamine 2000
(Invitrogen, Paisley, UK) following the manufacturer’s
instructions.
Animal models
ICRF nude mice (Cancer Research UK) were used
for the IGROV-1 experiments. C57 Black6 mice
(Charles River, Margate, UK) were used for all
ID8 experiments. Briefly, IGROV-1 (5× 106 cells)
and ID8 (1× 107 cells) were injected in 0.3 ml
of sterile, endotoxin-free PBS. The animals would
reach UKCCCR guidelines for end-point tumour bur-
den [11] in approximately 5 and 12 weeks, respec-
tively.
Intravital microscopy (IVM)
The protocol for mesenteric IVM has been described
previously [12]. Body temperature was maintained at
37 ◦C and mice were anaesthetized with i.p. ketamine
(150 mg/kg) and xylazine (7.5 mg/kg). A midline inci-
sion (1.5 cm) was made through the skin and the
peritoneal wall. The mesentery was positioned over
a Perspex viewing stage and observed using a water
immersion objective on a Zeiss Axioskop FS micro-
scope (Carl Zeiss, Welwyn Garden City, UK). The
number and size of the tumour deposits were recorded
in a 0.4 mm2 area.
Fluorescent labelling of the mesentery
Functional blood vessel labelling was achieved by
injecting (i.v.) 100 μl of 2 mg/ml lectin solution
(TRITC-conjugated Bandeiraea simplicifolia lectin;
Sigma Aldrich, Dorset, UK) or streptavidin Alexa
633 conjugated to biotin-tagged Lycopersicon esculen-
tum lectin (Invitrogen and Vector Labs, Peterborough,
UK, respectively) under terminal anaesthesia. The ani-
mals were then killed via cardiac perfusion of a 4%
paraformaldehyde (PFA) solution. The mesenteric tis-
sue was removed, washed, and fixed in 4% PFA for
1 hour. The tissue was then blocked and permeabilized
in a blocking solution of 3% goat serum, 1% BSA, and
1% Triton-X100. Staining for a variety of cell markers
was achieved using both fluorophore-conjugated pri-
mary antibodies (eg SMA-Cy3 from Sigma; MRP14
conjugated to Alexafluor 555, a kind gift from Profes-
sor N Hogg, CRUK; and CD3-Alexa 647 from eBio-
science, Hatfield, UK) and primary antibodies with
fluorescently labelled secondary antibodies [eg F4/80
(a mouse macrophage-specific marker) with anti-rat
DyLight™ 405 from ABD Serotec, Kidlington, UK and
CD45 (a common marker for all nucleated haemopoi-
etic cells) from BD, Oxford, UK with anti-rat Alexa
633]. MRP14 was used as a tissue neutrophil marker
as it labels calcium-binding proteins highly expressed
on neutrophils and monocytes. Tissues were washed in
PBS and arranged on a slide. The intestine was then
removed before embedding the tissue onto the slide in
Prolong Gold (Invitrogen). The mesenteric tissue was
imaged on both an Ariol computer-controlled micro-
scope (Leica Microsystems, Gateshead, UK) and image
analysis system and a Zeiss LSM 510 confocal micro-
scope.
Human tumour samples
Human omentum samples were collected from surgery
on ovarian cancer patients at St Bartholomew’s Hospi-
tal. Samples were taken from patients who had given
prior consent under the Research Ethical Committee
Project number 10/H0304/14 and stored within the
Barts Gynae Tissue Bank. Sections of human omen-
tal tissue were stained for the immunohistochemical
markers CD68 (a marker for all human cells of the
macrophage lineage) (Dako, Ely, UK) and CD3 (found
on all mature human T cells) (Labvision, Cuncorn, UK)
using a Dako Autostainer Plus with a Super Sensi-
tive Polymer—HRP DAB (Launch Diagnistics Ltd,
Longfield, U.K.). Neutrophil elastase (a marker for
human neutrophils) (Dako) and α-SMA (a marker for
fibroblasts and pericytes) (Sigma) staining was visu-
alized with a biotinylated HRP secondary antibody
and DAB staining (Vector Labs). Quantification of the
tumour-infiltrating inflammatory cells was determined
using the Ariol computer-controlled microscope (Leica
Microsystems) and image analysis system. Six of the
samples were obtained from patients who had inter-
val debulking surgery after three cycles of carboplatin
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Figure 1. Leukocytes and α-smooth muscle actin (α-SMA)-positive cells in omental tumour deposits of high-grade serous ovarian cancer.
Immunohistochemistry was carried out on omental tumour deposits removed at surgery. (A) Representative images of a section from
patient G11. Clockwise from top left: CD3+, CD68+, α-SMA+, and neutrophil elastase+ (NE+) cells. Scale bar = 400 μm. (B) The
tumour-infiltrating leukocytes were measured in each entire tissue section using the Ariol computer-controlled microscope and are
expressed as a percentage of positively stained cells relative to a haematoxylin nucleus counterstain. All values represent mean and
standard deviations. n = 8 patients.
and paclitaxel chemotherapy; two were obtained from
patients undergoing primary debulking surgery.
Results
Peritoneal metastases of human high-grade serous
ovarian cancer
We first examined the cellular composition of micro-
scopic peritoneal tumour deposits from eight patients
with HGSC, using omentum removed during cytore-
ductive surgery. All deposits had prominent infiltrates
of CD3+ lymphocytes and CD68+ macrophages, but
there were few neutrophil elastase-positive cells. The
deposits were well-vascularized and had many α-SMA-
positive pericytes and fibroblasts (Figure 1A). Using
Ariol computer-controlled microscopy, we calculated
the percentage of each leukocyte population per total
number of cells in the peritoneal tumour islands, assess-
ing an entire tissue section for each of the deposits.
Figure 1B shows that 12% of the cells were CD3+ T
cells and 14% of the cells were CD68+ macrophages.
Less than 1% of the cells in the tumour deposits were
neutrophils.
Peritoneal metastases of ovarian cancer cells
in mice
We used the bowel mesentery as a readily accessi-
ble murine peritoneal location for temporal analysis
of cellular and molecular changes using both confo-
cal and intravital microscopy. In all experiments, we
used two well-characterized transplantable models of
ovarian cancer that grow intraperitoneally: IGROV-
1 human HGSC xenografts [8,10] and the ID8 syn-
geneic mouse ovarian cancer model [7,9]. Both cell
lines expressed eGFP. An Ariol computer-controlled
microscope imaged the entire bowel mesentery for
deposits of eGFP-expressing tumour cells. Vascula-
ture was labelled with red TRITC-labelled Bandeiraea
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Figure 2. The development of ovarian cancer deposits on the
bowel mesentery. Ariol computer-controlled microscopy provided
a global view of the colonization of malignant cells on the surface
of the mesothelium. (A) A representative image of the colonization
of the bowel mesentery with ID8 tumour deposits (green) and
the functional vasculature (BS-1 lectin—red). Scale bar = 1 mm.
(B) The colonization of the bowel mesentery by tumour cell deposits
was measured by the Ariol microscope software by comparing the
area of Hoechst staining with the area of the eGFP tumour staining.
(Solid bars are the ID8 tumour deposits and the open bars are the
IGROV-1 tumour deposits.) The results for the ID8 cells showed a
significant increase in the tumour cell area over a 2-week period
(p = 0.01, Student’s t-test). n = 6 animals per time point for ID8
and n = 3 animals for IGROV-1.
simplicifolia lectin. Figure 2A shows a representa-
tive image of the bowel mesentery 10 weeks after
injection of eGFP-expressing ID8 cells. Similar pat-
terns of spread were observed in a xenograft setting
with IGROV-1 cells. A majority of the deposits were
located close to existing peritoneal vessels, although
some developed in avascular areas. The area of the
mesentery that was occupied by eGFP-labelled cells
also increased with time, as shown in a typical exper-
iment with ID8 cells (Figure 2B). At 3 weeks, com-
parable values for IGROV-1 cells were approximately
3% of the mesenteric area (Figure 2B). This reflected
the natural history of these two models in our labora-
tory; the end point of the ID8 model was approximately
12 weeks [9], whereas the IGROV-1 end point was
4–6 weeks [8].
Intravital microscopy of the tumour-bearing bowel
mesentery
To enable us to study the development of tumour
deposits in live animals, an intravital microscopy tech-
nique established for studying peritoneal inflammation
[12] was used to study peritoneal tumour growth and
attachment in more detail. For this purpose, mice were
injected with eGFP-labelled malignant cells and at
time points between 48 h and 10 weeks, the bowel
mesentery was exteriorized under terminal anaesthe-
sia (Figure 3A). Malignant cells were clearly visible
in the avascular areas of the mesentery, as observed
by both phase contrast and fluorescence microscopy
(Figures 3B and 3C). As deposits above and around the
existing blood vessels were difficult to image because
of surrounding adipose tissue, we focused on areas
between the vessels (see Figure 3A).
All such IGROV-1 deposits were avascular for the
first 2 weeks. However, by 3 weeks, blood vessels
began to spread across the avascular mesenteric spaces
towards the malignant cells. At 3 weeks, these ves-
sels had poor flow and were mostly incomplete. After
this time, tumour blood vessels developed rapidly and
within 6 weeks, most tumours larger than 100 μm
in diameter were vascularized with apparently viable
structures that could support a fast-moving and con-
voluted blood flow. (Figure 3C shows this sequence
for IGROV-1.) The peritoneal deposits formed by ID8
murine ovarian cancer cells took longer to develop, as
expected from our knowledge of the natural history,
with new blood vessels developing at 4–6 weeks.
Supplementary Movie 1 (Supporting information)
shows the development of IGROV-1 tumours on the
bowel mesentery. The normal mesothelium is shown
at the beginning, followed by an early time point
(6 h post-i.p. injection of cells) where single malignant
cells are visible on the mesothelium. After 1 week,
the malignant cells showed signs of aggregation. Two
weeks after injection, IGROV-1 cells had formed large
deposits without a vasculature. The development of a
vasculature to the tumour was visible at 3 weeks post-
i.p. injection of IGROV-1 cells. The initial vessels
appeared as fine structures, and as can be seen in
the film, the single red blood cells within them were
moving slowly and were sometimes static. By 4 and
6 weeks, the vessels had developed into large structures
with an increased flow rate. These images are typical
of those obtained from at least three mice at each time
point. The images shown at different time points of
peritoneal development are from individual mice.
Colony number and size were recorded throughout
the experiments. For both the xenogeneic and the
syngeneic model, single cells and smaller deposits
of less than 100 μm in diameter were visible by
48 h (Figures 3D and 3E). In the IGROV-1 model,
the number of small deposits decreased by 1 week
and remained constant thereafter. Deposits larger than
100 μm increased in number steadily over the 6-week
time course of the experiment. The deposits also grew
Copyright © 2012 Pathological Society of Great Britain and Ireland. J Pathol 2012; 227: 136–145
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Figure 3. Imaging of tumour deposits on the bowel mesentery by intravital microscopy (IVM). (A) Image of a bowel mesentery preparation
as used for the IVM protocols from a dissecting microscope (original magnification ×10). (B) eGFP-transfected malignant cells clearly show
the colonization of the bowel mesothelium. Both single cells and larger tumour colonies could be seen. Scale bar = 10 μm. (C) Composite
panel showing the development of the IGROV-1 malignant cells on the bowel mesothelium. As mice were sacrificed after imaging,
each picture is taken from a different animal. Scale bar = 10 μm. Clockwise from top left: the pre-tumour bowel mesothelium with no
malignant cells; the initial colonization process of the malignant cells 48 h post-injection of malignant cells with single cells attached
to the mesothelium; the tumour 2 weeks post-i.p. injection with an avascular tumour formed on the surface of the tissue; a vascularized
tumour 4 weeks after injection of the cells. (D) Tumour deposits were counted by assessing 40 regions of the bowel mesentery (0.4 mm2).
The growth of the IGROV-1 malignant cells is shown over a 6-week time course (n = 3 animals per time point). (E) ID8 tumour deposits
were counted as in D but over a 10-week time course (n = 3 per time point). (D, E) Solid bars are colonies smaller than 100 μm in diameter.
Open bars are colonies larger than 100 μm.
Copyright © 2012 Pathological Society of Great Britain and Ireland. J Pathol 2012; 227: 136–145
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
Peritoneal deposits of serous ovarian cancer 141
Figure 4. Mesenteric tumour angiogenesis visualized using the
whole mount method. (A) The development of IGROV-1 tumours
on the bowel mesentery showing the recruitment of functional
blood vessels (LE lectin—yellow) and pericytes (anti-SMA—red).
Scale bar = 50 μm. (B) ID8 tumours develop over a longer time
course compared with the IGROV-1 tumours. However, the similar
recruitment of pericytes and functional vessels is visible. Scale bar
= 50 μm. (C) Comparison of the pericyte labelling and functional
blood vessels in the ID8 tumour model. The percentage of tumours
with either BS-1 lectin or anti-SMA labelling is displayed (six
tumours analysed per time point).
out from the surface of the bowel mesentery, reaching
estimated heights of between 2 and 3 mm at end point.
With ID8, the smaller deposits persisted throughout
the experiment and larger deposits were observed by
2 weeks. With both models, clusters of cells from the
larger deposits could be dislodged, suggesting that they
too may be able to disseminate elsewhere through the
peritoneal cavity.
The ‘angiogenic switch’ in the peritoneal tumour
islands
We next used confocal microscopy to further study the
development of blood vessels in the peritoneal deposits,
staining the mesothelium for functional blood ves-
sels (Lycopersicon esculentum lectin—yellow), fibrob-
lasts, and pericytes (α-SMA—red) with eGFP-positive
malignant cells. Figure 4A shows a typical image of
IGROV-1 tumour colony development, with vascula-
ture first evident between 3 and 4 weeks. Of note is that
α-SMA-positive ‘vascular shapes’ resembling blood
vessels were seen before functional blood vessels were
observed. In the ID8 model, the vasculature first devel-
oped between 4 and 8 weeks post-tumour cell injection
(Figure 4B); 25% of tumour deposits were vascular-
ized at 4 weeks but 100% at 10 weeks (Figure 4C). In
contrast, the percentage of tumour deposits containing
α-SMA-positive cells remained constant over the 4-
to 10-week observation period (Figure 4C), suggesting
that the pericyte ‘sheaths’ preceded functional blood
flow.
The leukocyte infiltrate in the peritoneal tumour
deposits
We next examined the leukocyte component of the
peritoneal tumour deposits by confocal microscopy
using CD45 as a pan-leukocyte marker and red TRITC-
labelled lectin as a marker of functional blood ves-
sels. CD45+ cells were rarely detected on the bowel
mesentery from control mice or in areas of mesen-
tery from tumour-bearing mice that were tumour-
free. Within 48 hours of IGROV-1 cell injection, we
found leukocytes accumulating around the tumour cell
deposits. This leukocyte infiltrate persisted and pre-
ceded the development of blood vessels at 3–4 weeks
(Figure 5A). As the ID8 model had a slower natu-
ral history, we studied this from 2 to 10 weeks after
tumour cell injection. Once again, a prominent CD45+
leukocyte infiltrate preceded the development of a
vasculature to the deposits (Figure 5B). As we had
observed with the omental tumour deposits from the
HGSC patients, the leukocytes were predominantly
CD3+ T cells and F4/80+ macrophages in the ID8
model (Figures 5C and 5D). There were few MRP14+
cells after 2 weeks.
Manipulation of CXCR4 expression
The results described above show that we can model
the development of peritoneal deposits of ovarian can-
cer in mice and that the leukocyte populations resem-
ble those seen in human HGSC. We therefore asked
if we could use our methods to measure changes in
tumour development. We chose to assess the effects
of manipulating expression of the chemokine recep-
tor CXCR4 on peritoneal tumour deposits, as we, and
others, have found this receptor to be important in ovar-
ian cancer growth and spread [8,13–15]. Moreover,
we recently reported that stable knockdown of CXCR4
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Figure 5. Imaging and quantifying the leukocyte recruitment to mesenteric ovarian tumour deposits. (A) Using immunofluorescence, the
IGROV-1 tumours (green) on the bowel mesentery were labelled for immune infiltrate (anti-CD45—purple) and functional blood flow (red).
Representative images over a 4-week time course are shown. (B) Using the same labelling as in A, the immune infiltrate and functional
blood flow are shown in the ID8 tumour model over a 10-week time period. (C) The different immune cell infiltrate within the ID8 tumour
(green) was further characterized by staining for CD3+ (purple), F4/80+ (turquoise), and MRP14+ cells (red) (representative images shown).
(D) The tumour volume and immune infiltrate (expressed as number of each cell type per 100000 μm3 tumour volume) from the ID8 tumour
were quantified using IMARIS analysis software of the CLSM images (18 tumours from six mice). All scale bars = 50 μm. The increase in
tumour volume with time was statistically significant (p < 0.01, Student’s t-test). All differences in composition of the leukocyte infiltrate
between 2 and 4 or 8 weeks were also significant (p < 0.05, Student’s t-test).
reduced tumour growth in vivo, as measured by imag-
ing of luciferase-transfected cells [10]. The efficacy
of the CXCR4 knockdown and the lack of effect on
in vitro growth and viability of these cells have already
been published by us [10]. IGROV-1 cells mock-
transfected or transfected with shRNA to CXCR4 were
injected i.p. and peritoneal tumour colony formation
was assessed over a 6-week time period using intrav-
ital and confocal microscopy. Intravital microscopy
showed that more mock-transfected than shCXCR4
tumour cells had adhered to the mesentery in the time
period 48 h–2 weeks. Control deposits developed and
grew in size as expected. Viable single cells and small
deposits remained on the mesentery in the shCXCR4
group but the number of deposits 100 μm in diameter
or more was greatly reduced (p < 0.001) (Figures 6A
and 6B). Confocal microscopy revealed a diminished
vasculature in the shCXCR4 deposits (Figure 6C). We
also used IMARIS analysis to measure tumour vol-
ume and CD45+ leukocyte density. At 4 weeks, there
was a significant decrease in tumour volume and at 1
week a significant decrease in leukocyte count stan-
dardized to tumour volume (Figures 6D and 6E) (both
p < 0.001).
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Figure 6. Measuring the effect of CXCR4 shRNAi on the mesenteric development of IGROV-1 ovarian tumours. IVM analysis of the growth
of the CXCR4 shRNA IGROV-1 tumours is displayed on the two graphs (black bars—shScrambled IGROV-1 cells; open bars—shCXCR4
IGROV-1).(A) Effect of shCXCR4 on the growth of IGROV-1 cell colonies smaller than 100 μm. (B) Effect of shCXCR4 on the growth of
IGROV-1 cell colonies larger than 100 μm. Inhibition of tumour growth was recorded in the larger IGROV-1 deposits, p < 0.001 (six mice
per time point). (C) Representative images of the leukocyte recruitment (CD45+ cells—purple) and functional blood (BS-1 lectin—red) in
both mock and shCXCR4 IGROV-1 tumours over a 4-week time period. (D) Measurement of the tumour volume using IMARIS analysis
software. ∗p < 0.001, Bonferroni post-test. (E) The density of CD45+ leukocytes. ∗p < 0.001, Bonferroni post-test). All scale bars = 50 μm.
Discussion
Traditional concepts of metastasis may not apply to
some types of ovarian cancer. In HGSC, there is no
anatomical barrier to seeding throughout the peritoneal
cavity. At the earliest detectable stage, the disease may
have already formed multiple small peritoneal deposits
and these can probably be generated from a primary
cancer no larger than a few centimetres [2,5]. Any
therapeutic approach to this disease therefore needs
to take into account an understanding of the devel-
opment of peritoneal deposits and their response to
treatment. Here we have shown that in experimental
mouse models, ovarian cancer cells injected intraperi-
toneally attach rapidly to avascular areas of the peri-
toneal surface, forming vascularized deposits. These
tumour deposits contain substantial infiltrates of lym-
phocytes, macrophages, and fibroblasts/pericytes that
mimic the composition of those found in patients with
advanced HGSC. After i.p. injection, the malignant
cells also formed deposits over the vascular areas of
the bowel mesentery and some of these may have
been associated with milky spots as described by Ger-
ber et al [16]. However, we conclude that, at least
on the bowel mesentery, malignant cells can attach
to mesothelial cell monolayers and then recruit their
own microenvironment of leukocytes and new blood
vessels.
The infiltrating leukocytes found in primary human
HGSC tumours are related to both good and bad
prognosis, depending on subtype. Increased infiltra-
tion of CD8+ lymphocytes in solid tumour islets pre-
dicts longer survival [17] and correlates significantly
with BRCA loss [18]. On the other hand, high num-
bers of CD4+ T-regulatory cells, which can medi-
ate immune suppression, predict poor patient survival
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[19,20]. Additional immunosuppressive leukocyte sub-
types, such as B7-H4-expressing tumour macrophages
[21], have also been correlated with poor outcome in
ovarian cancer.
Six of the eight patients studied had already received
three cycles of chemotherapy. As a majority of HGSC
patients in the UK are now pretreated before surgery,
we could only obtain two chemo-naı¨ve samples. We
could see no difference between untreated and treated
in terms of deposit size, location or the CD3+ and NE+
infiltrate but there did seem to be fewer CD68+ cells
in the treated patients.
We believe that any pre-clinical studies of HGSC
in mouse models should study peritoneal spread, as
this is the major clinical challenge. There is evidence
for a cancer stem cell (CSC) population in HGSC
with the capacity for both self-renewal and generating
heterogeneous lineages [22–25], and we expect that
this stem cell component will be a major determinant
of cell behaviour in vivo [23]. It is likely that the
tumour deposits that have colonized the peritoneum
in the mouse models are derived from these CSCs.
We have shown that in HGSC there is an autocrine
cytokine network in the malignant cells, with the major
players being CXCR4, CXCL12, TNF-α, and IL-6. We
have named this the TNF network. This network has
paracrine tumour-promoting actions on the leukocyte
infiltrate and angiogenesis [10]. The results presented
here show that inhibiting the TNF network via stable
CXCR4 knockdown can have profound effects on the
development of peritoneal deposits. Viable malignant
cells survived attached to the peritoneal surface but
few developed any vasculature. Treatment of HGSC
with cytokine or chemokine antagonists, eg anti-IL-
6 antibodies [26], may be one way to delay or
inhibit further development of peritoneal disease after
diagnosis and initial chemotherapy and surgery.
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